

COPY OF PAPERS
ORIGINALLY FILED
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Receipt

Applicant: WU et al.
Serial No.: 09/904,251
Filed: 12 July 2002



Examiner: unknown
Group Art Unit: 1653
Docket: 9555.94US11

Title: USE OF PROTEASOME INHIBITORS FOR TREATING CANCER, INFLAMMATION,
AUTOIMMUNE DISEASE, GRAFT REJECTION AND SEPTIC SHOCK

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: , Commissioner for Patents, Washington, D.C. 20231 on May 22, 2002.

By: 
Name: Heidi Hanson

Commissioner for Patents
Washington, D.C. 20231

Sir:


We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Other: Request for Corrected Filing Receipt, Copy of Filing Receipt with corrections noted in red ink
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300




By: 
Name: Gregory A. Sebold
Reg. No.: 33,280
GAS:hjh

RECEIVED

JUL 5 2002

TECH CENTER 1600/2900



S/N 09/904251



COPY OF PAPERS
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	WU et al.	Examiner:	unknown
Serial No.:	09/904,251	Group Art Unit:	1653
Filed:	12 July 2001	Docket No.:	9555.94USI1
Title:	USE OF PROTEASOME INHIBITORS FOR TREATING CANCER, INFLAMMATION, AUTOIMMUNE DISEASE, GRAFT REJECTION AND SEPTIC SHOCK		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on 22 May 2002.

By:

Name: Heidi Hanson

REQUEST FOR CORRECTED FILING RECEIPT

Office of Initial Patent Examination's Customer Service Center
Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JUL 5 2002

TECH CENTER 1600/2900

Dear Sir:

Enclosed is a photocopy of the filing receipt from the United States Patent and Trademark Office in the above-identified application showing requested corrections.

The DOMESTIC PRIORITY DATA is incorrect.

Please replace "08/25/1999" with --06/29/1999--.


Correction of the records of the United States Patent and Trademark Office and issuance of a corrected filing receipt are respectfully solicited.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: 22 May 2002

By


Gregory A. Sebald
Reg. No. 33,280

GAS:hjh



COPY OF PAPERS
ORIGINALLY FILED

Page 1 of 2

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/904,251	07/12/2001	1653	420	9555.94US11	34	12	1

23552 *GAS*
MERCHANT & GOULD PC
P.O. BOX 2903
MINNEAPOLIS, MN 55402-0903

CONFIRMATION NO. 3075

UPDATED FILING RECEIPT



0C00000007304711

Date Mailed: 01/14/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jiangping Wu, Brossard, CANADA;
Xin Wang, Montreal, CANADA;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/218,145 07/14/2000
AND A CIP OF 09/341,009 08/25/1999 *"
WHICH IS A 371 OF PCT/CA98/01010 10/29/1998
(*) Data Inconsistent with PTO records.

-- 06/29/1999 --

Foreign Applications

If Required, Foreign Filing License Granted 07/30/2001

Projected Publication Date: 04/25/2002

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a security order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).